While Congress focuses on high-stakes health care reform issues that will likely affect every health system stakeholder over the next few years, and may radically change the reimbursement environment and market potential of emerging device and diagnostic technologies, business as usual goes on — for better or for worse — for individual companies.
One of the companies experiencing “for worse” is CardioNet (NASDAQ:BEAT), the once high-flying Pennsylvania-based cardiac monitoring company touted by many as the best pure play in wireless patient monitoring and diagnostics.